Product Code: SR112024A4907
The global single cell multiomics market size reached US$ 4.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 15.0 Billion by 2032, exhibiting a growth rate (CAGR) of 15.4% during 2024-2032.
Single cell multiomics refers to the analysis of multiple types of molecules from an individual cell to gain insights regarding cellular diversity and heterogenity. It involves single cell genomics, proteomics, transcriptomics and metabolomics and is widely used in neurology, immunology, cell biology and oncology. Single cell multiomics aids in enhancing the understanding of population architectures and cellular properties of heterogeneous tissues. It utilizes single cell isolation and dispensing techniques to provide images of the molecular layers and complex biological structures. In comparison to the traditionally used live-cell fluorescence imaging techniques, single-cell multi-omics does not involve the destruction of cells for analysis and can measure multiple types of the molecule from a single cell. As a result, it is widely used across biotechnology and pharmaceutical organizations, hospitals, academics and research institutes and diagnostic laboratories.
Single Cell Multiomics Market Trends:
The rising prevalence of chronic diseases, such as cancer and communicable viral diseases, is one of the key factors driving the growth of the market. Single cell multiomics provides a high-resolution landscape of cellular components in the tumors. Additionally, the widespread product adoption for visualization and analysis of cell heterogeneity, tumor micro-environment and antibody development are favoring the market growth. Moreover, various technological advancements, such as the development of single-cell isolation and barcoding technologies that enable deoxyribonucleic acid (DNA), messenger ribonucleic acid (mRNA) and protein profiles to be measured at a single-cell resolution, are providing a thrust to the market growth. In line with this, significant growth in the pharmaceutical industry is positively impacting the market growth. Other factors, including the increasing adoption of personalized medicine for the treatment of genetic disorders, along with the extensive improvements in the healthcare infrastructure, are anticipated to drive the market toward growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global single cell multiomics market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, product type, technique, application and end user.
Breakup by Type:
Single Cell Genomics
Single Cell Proteomics
Single Cell Transcriptomics
Single Cell Metabolomics
Breakup by Product Type:
Consumables
Instruments
Software
Breakup by Technique:
Single-Cell Isolation and Dispensing
Single-Cell Analysis
Breakup by Application:
Oncology
Cell Biology
Neurology
Others
Breakup by End User:
Academic Institutes
Contract Research Organizations
Pharmaceutical and Biotech Companies
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being 10x Genomics Inc., Becton Dickinson and Company, BGI Genomics (BGI Group), Bio-RAD Laboratories Inc., Fluidigm Corporation, Illumina Inc., Mission Bio, NanoCellect Biomedical, Nanostring Technologies Inc., Proteona, Takara Bio Inc. (Takara Holdings) and Thermo Fisher Scientific Inc.
Key Questions Answered in This Report
- 1. What was the size of the global single cell multiomics market in 2023?
- 2. What is the expected growth rate of the global single cell multiomics market during 2024-2032?
- 3. What has been the impact of COVID-19 on the global single cell multiomics market?
- 4. What are the key factors driving the global single cell multiomics market?
- 5. What is the breakup of the global single cell multiomics market based on the type?
- 6. What is the breakup of the global single cell multiomics market based on the product type?
- 7. What is the breakup of the global single cell multiomics market based on the technique?
- 8. What is the breakup of the global single cell multiomics market based on the application?
- 9. What is the breakup of the global single cell multiomics market based on the end user?
- 10. What are the key regions in the global single cell multiomics market?
- 11. Who are the key players/companies in the global single cell multiomics market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Single Cell Multiomics Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Type
- 6.1 Single Cell Genomics
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Single Cell Proteomics
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Single Cell Transcriptomics
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Single Cell Metabolomics
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
7 Market Breakup by Product Type
- 7.1 Consumables
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Instruments
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Software
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
8 Market Breakup by Technique
- 8.1 Single-Cell Isolation and Dispensing
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Single-Cell Analysis
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
9 Market Breakup by Application
- 9.1 Oncology
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Cell Biology
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Neurology
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
- 9.4 Others
- 9.4.1 Market Trends
- 9.4.2 Market Forecast
10 Market Breakup by End User
- 10.1 Academic Institutes
- 10.1.1 Market Trends
- 10.1.2 Market Forecast
- 10.2 Contract Research Organizations
- 10.2.1 Market Trends
- 10.2.2 Market Forecast
- 10.3 Pharmaceutical and Biotech Companies
- 10.3.1 Market Trends
- 10.3.2 Market Forecast
11 Market Breakup by Region
- 11.1 North America
- 11.1.1 United States
- 11.1.1.1 Market Trends
- 11.1.1.2 Market Forecast
- 11.1.2 Canada
- 11.1.2.1 Market Trends
- 11.1.2.2 Market Forecast
- 11.2 Asia-Pacific
- 11.2.1 China
- 11.2.1.1 Market Trends
- 11.2.1.2 Market Forecast
- 11.2.2 Japan
- 11.2.2.1 Market Trends
- 11.2.2.2 Market Forecast
- 11.2.3 India
- 11.2.3.1 Market Trends
- 11.2.3.2 Market Forecast
- 11.2.4 South Korea
- 11.2.4.1 Market Trends
- 11.2.4.2 Market Forecast
- 11.2.5 Australia
- 11.2.5.1 Market Trends
- 11.2.5.2 Market Forecast
- 11.2.6 Indonesia
- 11.2.6.1 Market Trends
- 11.2.6.2 Market Forecast
- 11.2.7 Others
- 11.2.7.1 Market Trends
- 11.2.7.2 Market Forecast
- 11.3 Europe
- 11.3.1 Germany
- 11.3.1.1 Market Trends
- 11.3.1.2 Market Forecast
- 11.3.2 France
- 11.3.2.1 Market Trends
- 11.3.2.2 Market Forecast
- 11.3.3 United Kingdom
- 11.3.3.1 Market Trends
- 11.3.3.2 Market Forecast
- 11.3.4 Italy
- 11.3.4.1 Market Trends
- 11.3.4.2 Market Forecast
- 11.3.5 Spain
- 11.3.5.1 Market Trends
- 11.3.5.2 Market Forecast
- 11.3.6 Russia
- 11.3.6.1 Market Trends
- 11.3.6.2 Market Forecast
- 11.3.7 Others
- 11.3.7.1 Market Trends
- 11.3.7.2 Market Forecast
- 11.4 Latin America
- 11.4.1 Brazil
- 11.4.1.1 Market Trends
- 11.4.1.2 Market Forecast
- 11.4.2 Mexico
- 11.4.2.1 Market Trends
- 11.4.2.2 Market Forecast
- 11.4.3 Others
- 11.4.3.1 Market Trends
- 11.4.3.2 Market Forecast
- 11.5 Middle East and Africa
- 11.5.1 Market Trends
- 11.5.2 Market Breakup by Country
- 11.5.3 Market Forecast
12 SWOT Analysis
- 12.1 Overview
- 12.2 Strengths
- 12.3 Weaknesses
- 12.4 Opportunities
- 12.5 Threats
13 Value Chain Analysis
14 Porters Five Forces Analysis
- 14.1 Overview
- 14.2 Bargaining Power of Buyers
- 14.3 Bargaining Power of Suppliers
- 14.4 Degree of Competition
- 14.5 Threat of New Entrants
- 14.6 Threat of Substitutes
15 Price Analysis
16 Competitive Landscape
- 16.1 Market Structure
- 16.2 Key Players
- 16.3 Profiles of Key Players
- 16.3.1 10x Genomics Inc.
- 16.3.1.1 Company Overview
- 16.3.1.2 Product Portfolio
- 16.3.1.3 Financials
- 16.3.2 Becton Dickinson and Company
- 16.3.2.1 Company Overview
- 16.3.2.2 Product Portfolio
- 16.3.2.3 Financials
- 16.3.2.4 SWOT Analysis
- 16.3.3 BGI Genomics (BGI Group)
- 16.3.3.1 Company Overview
- 16.3.3.2 Product Portfolio
- 16.3.3.3 Financials
- 16.3.4 Bio-RAD Laboratories Inc.
- 16.3.4.1 Company Overview
- 16.3.4.2 Product Portfolio
- 16.3.4.3 Financials
- 16.3.4.4 SWOT Analysis
- 16.3.5 Fluidigm Corporation
- 16.3.5.1 Company Overview
- 16.3.5.2 Product Portfolio
- 16.3.5.3 Financials
- 16.3.6 Illumina Inc.
- 16.3.6.1 Company Overview
- 16.3.6.2 Product Portfolio
- 16.3.6.3 Financials
- 16.3.6.4 SWOT Analysis
- 16.3.7 Mission Bio
- 16.3.7.1 Company Overview
- 16.3.7.2 Product Portfolio
- 16.3.8 NanoCellect Biomedical
- 16.3.8.1 Company Overview
- 16.3.8.2 Product Portfolio
- 16.3.9 Nanostring Technologies Inc.
- 16.3.9.1 Company Overview
- 16.3.9.2 Product Portfolio
- 16.3.9.3 Financials
- 16.3.10 Proteona
- 16.3.10.1 Company Overview
- 16.3.10.2 Product Portfolio
- 16.3.11 Takara Bio Inc. (Takara Holdings)
- 16.3.11.1 Company Overview
- 16.3.11.2 Product Portfolio
- 16.3.11.3 Financials
- 16.3.12 Thermo Fisher Scientific Inc.
- 16.3.12.1 Company Overview
- 16.3.12.2 Product Portfolio
- 16.3.12.3 Financials
- 16.3.12.4 SWOT Analysis